Loading, Please Wait...
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX).
To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cX
To read the full editorial, visit: http://nnw.fm/Y0ZqH
Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells. These are often viruses, turning a life form that is hostile to humanity into one that benefits us. In the case of Genprex’s Oncoprex treatment, the genes are carried in an intravenously delivered nanovesicle, or a tiny compartment like those found in cells. The Oncoprex nanovesicle is small enough to cross barriers into the lungs, where it can deliver its genetic material to the cancer site.
This uses one of two forms of gene therapy: gene replacement therapy. Currently, gene replacement therapies are the only ones approved by the FDA. The alternative, gene editing, has been the subject of various clinical trials but has not yet led to an approved treatment. For now, gene replacement therapy, or tackling unhealthy cells through the addition of healthy genes, is the proven way forward to gene therapy, and the approach appears to be serving Genprex well.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.